Data gathered: December 1
Data Bits
Data Bits | Value / Change | Benchmark | |
---|---|---|---|
Job Posts | 337 -3.2% |
|
|
Sentiment | 96 0% |
|
|
Webpage traffic | 577,000 3.2% |
|
|
Employee Rating | 78 0% |
|
|
Google Adspend | $40,739 N/A |
|
|
Google Trends | 12 -78.6% |
|
|
Linkedin Employees | 14,391 N/A |
|
|
Lobbying Cost | $797,000 0% |
|
|
NPS | 19 -9.5% | N/A | |
Patents | 489 0.2% |
|
|
4chan Mentions | 0% |
|
|
Facebook Engagement | 35 2.9% |
|
|
Facebook followers | 23,055 0% |
|
|
Stocktwits Mentions | 12 20% |
|
|
Stocktwits Subscribers | 76,064 0% |
|
|
Twitter Followers | 73,883 0% |
|
|
Youtube Subscribers | 5,120 0% |
|
|
Instagram Followers | N/A | N/A | |
News Mentions | -100% |
|
|
Reddit Mentions | 1 0% |
|
|
ESG | 82 0% |
|
|
Business outlook | 70 0% |
|
In the news
![]() |
17 Ideal Pre-Crash Recovery December Divi-DogsNovember 30 - SeekingAlpha |
2 Biotech Stocks You Can Buy and Hold for the Next DecadeNovember 29 - Yahoo |
|
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023November 29 - Yahoo |
|
Piper Sandler Reaffirms Their Buy Rating on Gilead Sciences (GILD)November 29 - TipRanks |
|
Gilead management to meet with OppenheimerNovember 29 - Thefly.com |
|
![]() |
Smart or AI In-Vitro Diagnostics Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce AnalyticNovember 29 - PR Newswire UK |
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Price | $77.36 |
Target Price | Sign up |
Market Cap | $93.7B |
Dividend Yield | 0.0399 |
Industry | Biotechnology |
Similar companies
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
---|---|---|---|---|---|
Q3 '23 | 6.82B | 3.48B | 3.34B | 2.18B | 3.16B |
Q2 '23 | 6.42B | 3.89B | 2.53B | 1.05B | 2.42B |
Q1 '23 | 6.12B | 3.27B | 2.85B | 1.01B | 2.1B |
Q4 '22 | 7.16B | 4.09B | 3.07B | 1.64B | 2.76B |
Q3 '22 | 6.82B | 3.05B | 3.77B | 1.79B | 3.11B |
Insider Transactions
Dickinson Andrew D filed to sell 104,003 shares at $80. October 18 '23 |
Parsey Merdad filed to sell 70,130 shares at $77. September 13 '23 |
Dickinson Andrew D filed to sell 107,587 shares at $80. July 21 '23 |
Parsey Merdad filed to sell 29,402 shares at $76.9. June 14 '23 |
Parsey Merdad filed to sell 70,130 shares at $79. March 14 '23 |